OIPE
AUG 30 2004
JC34
PATENT & TRADEMARK OFFICE

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 514712001500	Application Number 10/683,815
Applicant: Arnon ROSENTHAL et al.	
Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
Hand Delivered August 30, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
KAB	1.	08/30/2001	2001/0018053	McMichael			
	2.	01/24/2002	2002/0009445	Du et al.			
	3.	02/14/2002	2002/0019335	Solomon et al.			
	4.	07/04/2002	2002/0086847	Chain			
	5.	07/18/2002	2002/0094335	Chalifour et al.			
	6.	08/01/2002	2002/0102261	Raso			
	7.	09/06/1983	4,403,112	Modaferri			
	8.	11/27/1984	4,485,045	Regen			
	9.	10/01/1985	4,544,545	Ryan et al.			
	10.	07/29/1986	4,603,112	Paoletti et al.			
	11.	05/19/1987	4,666,829	Glenner et al.			
	12.	06/30/1987	4,676,980	Segal et al.			
	13.	07/28/1987	4,683,195	Mullis et al.			
	14.	07/28/1987	4,683,202	Mullis			
	15.	06/14/1988	4,751,180	Cousens et al.			
	16.	06/28/1988	4,754,065	Levenson et al.			
	17.	09/06/1988	4,769,330	Paoletti et al.			
	18.	10/11/1988	4,777,127	Suni et al.			
	19.	11/01/1988	4,782,014	Serban et al.			
	20.	01/24/1989	4,800,159	Mullis et al.			
	21.	03/28/1989	4,816,567	Cabilly et al.			
	22.	01/02/1990	4,891,268	Fourez et al.			
	23.	06/19/1990	4,935,233	Bell et al.			
↓	24.	05/07/1991	5,013,556	Woodle et al.			
KAB	25.	05/21/1991	5,017,487	Stunnenberg et al.			

EXAMINER: Kimberly Ballard DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Arnon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	26.	09/10/1991	5,047,335	Paulson et al.			
	27.	12/24/1991	5,075,109	Tice et al.			
	28.	11/17/1992	5,164,295	Kisilevsky et al.			
	29.	06/15/1993	5,219,740	Miller et al.			
	30.	07/27/1993	5,231,000	Majocha et al.			
	31.	08/10/1993	5,234,814	Card et al.			
	32.	11/16/1993	5,262,332	Selkoe			
	33.	12/14/1993	5,270,165	Van Nostrand et al.			
	34.	01/11/1994	5,278,299	Wong et al.			
	35.	01/31/1995	5,385,915	Buxbaum et al.			
	36.	06/06/1995	5,422,120	Kim			
	37.	08/15/1995	5,441,870	Seubert et al.			
	38.	03/19/1996	5,500,362	Robinson et al.			
	39.	04/23/1996	5,510,261	Goochee et al.			
	40.	06/11/1996	5,525,126	Basu et al.			
	41.	06/25/1996	5,530,101	Queen et al.			
	42.	08/13/1996	5,545,806	Longberg et al.			
	43.	08/13/1996	5,545,807	Surani et al.			
	44.	10/15/1996	5,565,332	Hoogenboom et al.			
	45.	10/29/1996	5,569,825	Lonberg et al.			
	46.	12/03/1996	5,580,717	Dower et al.			
	47.	12/03/1996	5,580,859	Felgner et al.			
	48.	12/17/1996	5,585,089	Queen et al.			
	49.	01/14/1997	5,593,846	Batt et al.			
	50.	02/18/1997	5,604,102	McConlogue et al.			
	51.	04/29/1997	5,625,126	Lonberg et al.			
	52.	05/27/1997	5,633,425	Lonberg et al.			
	53.	07/29/1997	5,652,092	Vitek et al.			
KAB	54.	08/26/1997	5,661,016	Lonberg et al.			

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Arnon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	55.	10/21/1997	5,679,531	König et al.			
	56.	12/02/1997	5,693,478	König et al.			
	57.	12/02/1997	5,693,753	König et al.			
	58.	12/02/1997	5,693,761	Queen et al.			
	59.	12/02/1997	5,693,762	Queen et al.			
	60.	02/03/1998	5,714,471	Rowe et al.			
	61.	02/24/1998	5,721,130	Seubert et al.			
	62.	03/31/1998	5,733,743	Johnson et al.			
	63.	04/14/1998	5,739,277	Presta et al.			
	64.	05/12/1998	5,750,349	Suzuki et al.			
	65.	05/12/1998	5,750,373	Garrard et al.			
	66.	07/28/1998	5,786,180	König et al.			
	67.	09/15/1998	5,807,715	Morrison et al.			
	68.	09/29/1998	5,814,482	Dubensky, Jr. et al.			
	69.	10/13/1998	5,821,337	Carter et al.			
	70.	12/22/1998	5,851,996	Kline			
	71.	02/02/1999	5,866,692	Shitara et al.			
	72.	04/06/1999	5,891,991	Wasco et al.			
	73.	08/24/1999	5,942,400	Anderson et al.			
	74.	09/21/1999	5,955,317	Suzuki et al.			
	75.	09/28/1999	5,958,684	Van Leeuwen et al.			
	76.	11/02/1999	5,976,817	Davies-Heerena et al.			
	77.	12/07/1999	5,997,867	Waldmann et al.			
	78.	04/25/2000	6,054,297	Carter et al.			
	79.	06/06/2000	6,071,463	De'ath			
	80.	08/22/2000	6,107,029	Giordano			
	81.	08/22/2000	6,107,050	Alkon et al.			
↓	82.	09/05/2000	6,114,133	Seubert et al.			
KAB	83.	11/07/2000	6,143,171	Van Aarsen			

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	84.	01/30/2001	6,180,370	Queen et al.			
	85.	01/30/2001	6,180,377	Morgan et al.			
	86.	02/13/2001	6,187,756	Lee et al.			
	87.	04/03/2001	6,210,671	Co			
	88.	04/24/2001	6,221,645	Chrysler et al.			
	89.	04/24/2001	6,221,670	Cordell et al.			
	90.	07/03/2001	6,255,054	Hugon et al.			
	91.	07/24/2001	6,265,150	Terstappen et al.			
	92.	09/25/2001	6,294,171	McMichael			
	93.	09/25/2001	6,294,340	Strittmatter et al.			
	94.	12/18/2001	6,331,415	Cabilly et al.			
	95.	02/26/2002	6,350,861	Co et al.			
	96.	04/23/2002	6,376,471	Lawrence, III et al.			
✓	97.	07/12/2002	6,413,942	Felgner et al.			
KAB	98.	08/20/2002	6,436,908	Koch et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
KAB	99.	12/06/1989	EP 0 345 242	Europe			Abstract	
	100.	10/10/1990	EP 0 391 714	Europe				
	101.	08/14/1991	EP 0 440 619	Europe				
	102.	12/23/1992	EP 0 519 596	Europe				
	103.	02/03/1993	EP 0 524 968	Europe				
	104.	08/31/1994	EP 0 613 007	Europe				
	105.	11/22/1995	EP 0 683 234	Europe				
	106.	12/05/2001	EP 1 160 256	Europe				
	107.	01/16/2002	EP 1 172 378	Europe				
	108.	08/10/1988	GB 2 200 651	Great Britain				
KAB	109.	07/30/1987	WO 87/04462	WIPO				

EXAMINER: Kimberly Ballard DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	110.	03/09/1989	WO 89/01973	WIPO				
	111.	07/26/1990	WO 90/07936	WIPO				
	112.	10/04/1990	WO 90/11092	WIPO				
	113.	12/13/1990	WO 90/14841	WIPO				
	114.	01/10/1991	WO 91/00360	WIPO				
	115.	03/07/1991	WO 91/02805	WIPO				
	116.	04/04/1991	WO 91/04339	WIPO				
	117.	10/03/1991	WO 91/14445	WIPO				
	118.	12/12/1991	WO 91/18926	WIPO				
	119.	03/04/1993	WO 93/03769	WIPO				
	120.	04/01/1993	WO 93/06213	WIPO				
	121.	05/27/1993	WO 93/10218	WIPO				
	122.	06/10/1993	WO 93/11230	WIPO				
	123.	09/30/1993	WO 93/19191	WIPO				
	124.	09/30/1993	WO 93/19194	WIPO				
	125.	12/23/1993	WO 93/25234	WIPO				
	126.	12/23/1993	WO 93/25698	WIPO				
	127.	02/17/1994	WO 94/03622	WIPO				
	128.	03/03/1994	WO 94/04690	WIPO				
	129.	06/09/1994	WO 94/12649	WIPO				
	130.	10/27/1994	WO 94/23697	WIPO				
	131.	12/22/1994	WO 94/28938	WIPO				
	132.	01/05/1995	WO 95/00655	WIPO				
	133.	03/23/1995	WO 95/07994	WIPO				
	134.	05/04/1995	WO 95/11984	WIPO				
	135.	05/18/1995	WO 95/13084	WIPO				
	136.	05/26/1995	WO 95/13796	WIPO				
	137.	11/16/1995	WO 95/30763	WIPO				
KAB	138.	06/06/1996	WO 96/17072	WIPO				

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	139.	08/22/1996	WO 96/25435	WIPO				
	140.	10/17/1996	WO 96/32105	WIPO				
	141.	12/19/1996	WO 96/40890	WIPO				
	142.	12/19/1996	WO 96/40896	WIPO				
	143.	11/13/1997	WO 97/42338	WIPO				
	144.	04/16/1998	WO 98/15179	WIPO				
	145.	06/11/1998	WO 98/24812	WIPO				
	146.	08/06/1998	WO 98/34120	WIPO				
	147.	09/11/1998	WO 98/39653	WIPO				
	148.	09/17/1998	WO 98/40484	WIPO				
	149.	10/15/1998	WO 98/44955	WIPO				
	150.	10/15/1998	WO 98/45444	WIPO				
	151.	10/22/1998	WO 98/46636	WIPO				
	152.	06/10/1999	WO 99/27944	WIPO				
	153.	11/18/1999	WO 99/58572	WIPO				
	154.	11/25/1999	WO 99/60024	WIPO				
	155.	11/23/2000	WO 00/69456	WIPO				
	156.	11/30/2000	WO 00/72280	WIPO			Abstract	
	157.	12/07/2000	WO 00/72876	WIPO				
	158.	03/15/2001	WO 01/18169	WIPO				
	159.	04/19/2001	WO 01/27160	WIPO				
	160.	06/07/2001	WO 01/39796	WIPO				
	161.	08/30/2001	WO 01/62801	WIPO				
	162.	10/18/2001	WO 01/ 77167	WIPO				
	163.	03/14/2002	WO 02/21141	WIPO				
	164.	05/16/2002	WO 02/38177	WIPO				
	165.	06/13/2002	WO 02/ 46237	WIPO				
	166.	09/12/2002	WO 02/070647	WIPO				
KAB	167.	09/27/2002	WO 02/074240	WIPO				

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Arnon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	168.	11/07/2002	WO 02/088306	WIPO				
KAB	169.	11/07/2002	WO 02/088307	WIPO				
KAB	170.	12/05/2002	WO 02/096937	WIPO				

	Ref. No.	Title
KAB	171.	Adelman, J.P. et al. (1983). "*In Vitro* Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," *DNA* 2(3):183-193.
	172.	Al-lazikami, B. et al. (1997). "Standard Conformations for the Canonical Structures of Immunoglobulins," *J. Molec. Biol.* 273:927-948.
	173.	Armour, K. L. et al. (1999). "Recombinant Human IgG Molecules Lacking Fcγ Receptor I binding and Monocyte Triggering Activities," *Eur. J. Immunol.* 29:2613-2624.
	174.	Bacskai, B. J. et al. (2001). "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," *Nature Medicine* 7(3):369-372.
	175.	Bacskai, B. J. et al. (2002). "Non –Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β *In Vivo* by Immunotherapy," *J. Neurosci* 22(18):7873-7878.
	176.	Baekelandt, V. et al. (2000). "Gene Therapeutic Strategies for Neurodegenerative Diseases," *Current Opinion in Molecular Therapeutics* 2(5):540-554.
	177.	Balint, R. G. et al. (1993). "Antibody Engineering by Parsimonious Mutagenesis," *Gene* 137(1):109-118.
	178.	Bamberger, ME. Et al. (2001). "Microglial Interaction with Beta-Amyloid: Implications for the the Pathologenesis of Alzheimer's Disease," *Microscopy Research and Techniques* 54(2):59-70.
	179.	Barbas, III C. F. et al. (1994) "In Vitro Evolution of a Neutralizing Human Antibody to Human Immnunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," *Proc. Nat. Acad. Sci USA* 91:3809-3813.
	180.	Bard, F. (2000). "Peripherally Administered Antibodies Against Amyloid β - Peptide Enter the Central Nervous System and reduce Pathology in a Mouse Model of Alzheimer Disease," *Nature Medicine* 6(8): 916-919
	181.	Berkner, K. L. (1988). "Development of Adenovius Vectors for the Expression of Heterologous Gene," *Biotechniques* 6:616-627.
	182.	Bird, R. E. et al. (1988). "Single-Chain Antigen-Binding Proteins," *Science* 242:423-426.
	183.	Blasko, I. et al. (2001). "Does IFN γ-Play A Role in Neurodegeneration," *Journal of Neuroimmunology* 116(1):1-4.
KAB	184.	Boerner, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies from In Vitro-Primed Human Splenocytes," *J. Immunol.* 147(1):86-95.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Arnon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	185.	Boncristiano, S. et al. (2002). "Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis," *The Journal of Neuroscience* 22(8):3234-3243.
	186.	Boyd, P. N. et al. (1996). "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," *Mol. Immunol.* 32(17/18):1311-1318.
	187.	Brayden, D.J. et al. (2001). "Encapsulation in Biodegradable Microparticles Enhances Serum Antibody Response to Parentally-Delivered β-Amyloid in Mice," *Vaccine* 19(30):4185-4193.
	188.	Brennan, M. et al. (1985). "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G_1 Fragments," *Science* 229:81-83.
	189.	Brown, B. A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," *Cancer Res.* 47:3577-3583.
	190.	Calhoun, M. E. et al. (1999). "Neuronal Overexpression of Mutant Amyloid Precursor Protein Results in Prominent Deposition of Cerebrovascular," *Neurobiology* 6(24):14088-14093.
	191.	Capel, P. J. A. et al. (1994). "Heterogeinity of Human lgG Fc Receptors," *Immunomethods* 4:25-34.
	192.	Carter, D. B et al. (2001). "Human Apolipoprotein E4 Accelerates Beta-Amyloid Deposition in APPsw Transgenic Mouse Brain," *Annals of Neurology* 50(4):468-475.
	193.	Carter, P. et al. (1992). "High Level Escherichia Coli Expression and Production of Bivalent Humanized Antibody Fragment," *Bio/Technology* 10:163-167.
	194.	Chartier-Harlin, M.-C. et al. (2001). "Un Espoir Thérapeutique Dans La Maladie D'Alzheimer, Ou ~~Peut-On Traiter Le Mal Par Le Mal,~~" ~~*M/S Nouvelles Medicine Sciences* 17(4):523-524 (Original~~ version).
	195.	Chauhan, N. B. et al. (2001). "Distribution of Intraventricularly Administered Antiamyloid-Beta Peptide (Aβ) Antibody in the Mouse Brain," *Journal of Neuroscience Research* 66:231-235.
	196.	Cherny, R.A et al (2001). "Treatment with A Copper-Zinc Chelator Markedly and Rapidly Inhibits Beta-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice," *Neuron* 30(3):665-676.
	197.	Chiou, H. C. et al. (1994). "In Vivo Gene Therapy via Receptor-Mediated DNA Delivery," *In* Gene Therapeutics: Methods and Applications of Direct Gene Transfer, Wolff, J. A., ed., Birkhauser, pp. 143-156.
	198.	Chishti, M.A. et al. (2001). "Early-Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein," *Journal of Biological Chemistry* 276(24):21562-21570.
	199.	Chothia, C. et al. (1989). "Conformations of Immunoglobulin Hypervariable Regions 395," *Nature* 342:877-883.
	200.	Chung, H.Y. et al. (2001). "Uptake of Fibrillar β-Amyloid by Microglia Isolated from MSR-A (Type I and Type II) Knockout Mice," *NeuroReport* 12(6):1151-1154.
	201.	Clakson, T. et al. (1991). "Making Antibody Fragments Using Phage Display Libraries," *Nature* 352:624-628.
KAB	202.	Clynes, R. et al. (1998). "Fc Receptors Are Required in Passive and Active Immunity to Melanoma,"

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

* DO NOT PRINT. NO ENGLISH TRANSLATION.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Arnon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

		PNAS USA 95:652-656.
KAB	203.	Cohen, J. (1993). "Naked DNA Points Way to Vaccines," *Science* 259:1691-1692.
	204.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," Monoclonal Antibodies and Cancer Therapy, Reisfeld, R. A. et al., Alan R.Liss, Inc., pp. 77-96.
	205.	Connelly, S. et al. (1995). "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," *Human Gene Therapy* 6:185-193.
	206.	Cunningham, B. C. et al. (1989). "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," *Science* 244:1081-1085.
	207.	Curiel, D. T. (1992). "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," *Hum.Gene Ther* 3:147-154.
	208.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Faciliates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," *Nucl. Acids Res.* 19(9):2471-2476.
	209.	Dayhoff, M.O. et al. (1978). "A Model of Evolutionay Change in Proteins," Chapter 22 *In* Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Volume 5, Supplemental 3 pp. 345-352.
	210.	De Strooper, B. et al. (2001). "Alzheimer's Disease: An Inflammatory Drug Prospect," *Nature* 414:159-160.
	211.	DeHaas, M. et al. (1995). "FCγ Receptors of Phagocytes," *J. Lab. Clin. Med.* 126(4):330-341.
	212.	DeMattos, R. B. (2001). "Peripheral Anti-Aβ Antibody Alters CNS and Plasma Aβ Burden in a Mouse Model of Alzheimer's Disease," PNAS 98(15):8850-8855.
	213.	DeMattos, R. B. et al. (2002). "Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease," *Science* 295:2264-2267.
	214.	Dodart, J.-C. et al. (2002). "Immunization Reverses Memory Deficits Without Reducing Brain Aβ Burden in Alzheimer's Disease Model," *Nat. Neuroscience* 5(5):452-457.
	215.	Duff, K. (1999). "Curing Amyloidosis: Will it Works in Humans," *Trends in Neurosciences* 22(11):485-486.
	216.	Duff, K. et al. (2001). "Progress in the Modeling of Neurodegenerative Diseases in Transgenic Mice," *Current Opinion in Neurology* 14(4):441-447.
	217.	El-Agnaf, O.M.A et al. (2001). "Non-Fibrillar Oligomeric Species of the Amyloid ABri Peptide, Implicated in Familial British Dementia, Are More Potent at Inducing Apoptotic Cell Death than Protofibrils or Mature Fibrils," *Journal of Molecular Biology* 310(1):157-168.
	218.	Eppstein, D. A. et al. (1985). "Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by A Cell Membrane Receptor," *PNAS USA* 82:3688-3692.
KAB	219.	Esiri, M. (2001). "Is an Effective Immune Intervention for Alzheimer's Disease in Prospect?" *Trends In Pharmacological Sciences* 22(1):2-3.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	220.	Fassbender, K. (2001). "Alzheimer's Disease: Molecular Concepts and Therapeutic Targets," *Naturwissenschaften* 88:261-267.
	221.	Findeis, M. A. et al. (1993). "Targeted Delivery of DNA for Gene Therapy via Receptors," *TibTech* 11:202-205.
	222.	Fisher-Hoch, S. P. et al. (1989). "Protection of Rhesus Monkeys from Fatal Lassa Fever by Vaccination with A Recombinant Vaccina Virus Containing the Lassa Virus Glycoprotein Gene," *PNAS USA* 86:317-321.
	223.	Fishman, C.E. et al. (2001). "Statistical Aspects of Quantitative Image Analysis of β-Amyloid in the APP^{V717F} Transgenic Mouse Model Alzheimer's Disease," *Journal of Neuroscience Methods* 108(2):145-152.
	224.	Flexner, C. et al (1990). "Attenuation and Immunogenicity in Primates of Vaccinia Virus Recombinants Expressing Human Interleukin-2," *Vaccine* 8:17-21.
	225.	Frenkel, D. et al. (2000). "Immunization Against Alzheimers' β-Amyloid Plaques via EFRH Phage Administration," *PNAS* 97(21):11455-11459.
	226.	Fukuta, T. (2001). "Difference in Toxicity of β-Amyloid Peptide with Aging in Relation to Nerve Growth Factor Content in Rat Brain," *Journal of Neural Transmission* 108(2):221-230.
	227.	Galasko, D. (2001). "New Approaches to Diagnose and Treat Alzheimer's Disease – A Glimpse of the Future," *Clinic in Geriatric Medicine* 17(2):393-410.
	228.	Garcia, P. et al. (1986). "Nucleotide Sequence and Expression of the Pneumococcal Autolysin Gene from Its Own Promoter In *Escherichia Coli*," *Gene* 43:265-272.
	229.	Gazzano-Santoro, H. et al. (1997). "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody," *J. Immunol. Methods* 202:163-171.
	230.	Geerligs, H. et al. (1989). "The Influence of Different Adjuvants on the Immune Response to a Synthetic Peptide Comprising Amino Acid Residues 9-21 of Herpes simplex Virus Type 1 Glycoprotein D," *J. Immunol. Methods* 124(1):95-102.
	231.	Griffith, A. D. et al. (1993). "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries," *EMBO J.* 12(2):725-734.
	232.	Guyer, R. L. et al. (1976). "Immunologlobulin Binding by Mouse Intestinal Epithelial Cell Receptors," *J. Immunol.* 117(2):587-593.
	233.	Guzman, R. J. et al. (1993). "Efficient and Selective Adenovirus-Mediated Gene Transfer Itno Vascular Neointima," *Circulation* 88(6):2838-2848.
	234.	Guzman, R. J. et al. (1993). "Efficient Gene Transfer Into Myocardium by Direct Injection of Adenovirus Vectors," *Cir. Res.* 73:1202-1207.
	235.	Haass, C. (2002). "New Hope for Alzheimer Disease Vaccine," *Nature Medicine* 8(11):1195-1196.
KAB	236.	Hadland, B.K. et al. (2001). "γ-Secretase Inhibitors Repress Thymocyte Development," *PNAS USA* 98(13):7487-7491.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	237.	Hardy, J. (1996). "New Insights Into the Genetics of Alzheimer's Disease," *Ann. Med.* 28:255-258.
	238.	Hardy, J. (1997). "Amyloid, the Presenilins and Alzheimer's Disease," *Trends Neurosci.* 20(4):154-159.
	239.	Hawkins, R. E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation," *J. Mol. Biol.* 226:889-896.
	240.	Hein, J. (1990). "Unified Approach to Alignment and Phylogenies" Chapter 39 *In* Methods of Enzymology, Academic Press, Inc., Volume 183 pp. 626-645
	241.	Higgins, D. G et al. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," *CABIOS Communications* 5(2):151-153.
	242.	Hock, C. et al. (2002). "Generation of Antibodies Specific for β-Amyloid by Vaccination of Patients with Alzheimer Disease," *Nature Medicine* 8(11):1270-1275.
	243.	Holcomb, L. A. et al. (1999). "Behavioral Changes in Transgenic Mice Expressing both amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Assocaition with Amyloid Deposits," *Behav. Gen.* 29(3):177-185.
	244.	Holcomb, L.A et al. (1998). "Accelerated Alzheimer-Type Phenotype in Transgenic Mice Carrying bot Mutant *Amyloid Precursor Protein* and *Presinilin* 1 Transgenes," *Nat. Med.* 4:97-100.
	245.	Holliger, P. et al. (1993). "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," *PNAS* 90:6444-6448.
	246.	Hoogenboom, H. R. et al. (1991). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V_H Gene Segments Rearranged in Vitro," *J. Mol. Biol.* 227:381-388.
	247.	Hoozemans, J.J.M. et al. (2001). "Immunological Aspects of Alzheimer's Disease- Therapeutic Implication," *BioDrugs* 15(5):325-337.
	248.	Hsiao, K. et al. (1996). "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaquest in Transgenic Mice," *Science* 274:99-102
	249.	Hsu, T.-A. et al. (1997). "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in *Triphoplusia ni* Cells," *J. Biol. Chem.* 272(14):9062-9070.
	250.	Huse, J. T et al. (2000). "Closing in on the Amyloid Cascade Recent Insights Into the Cell Biology of Alzheimer's Disease," *Molecular Neurobiology* 22(1-3):81-98.
	251.	Hwang, K. J. et al. (1980). "Hepatic Uptake and Degradation of Unilmellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study," *Proc. Natl Acad. Sci USA* 77(7):4030-4034.
	252.	Illiades, P. et al. (1997). "Triabodies: Single Chain Fv Fragments Without a Linker Form Trivalent Trimers," *FEBS Letters* 409:437-441.
↓	253.	Irizarry, M. C. et al. (2001). "Alzheimer Disease Therapeutics," *Journal of Neuropathology and Experimental Neurology* 60(10):923-928.
KAB	254.	Jackson, J. R. et al. (1995). "In Vitro Antibody Maturation," *J. Immunol.* 154(7):3310-3319.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	255.	Janus, C. et al. (2000). "Aβ Peptide Immunization Reduces Behavioural Impairment and Plaques in a Model of Alzheimer's Disease," *Nature* 408:979-982.
	256.	Janus, C. et al. (2001). "Transgenic Mouse Models of Alzheimer's Disease," *Physiology & Behavior* 73(5):873-886.
	257.	Jefferis R. et al. (1997). "Glycosylation of Antiody Molecules: Structural and Functional Significance," *Chem. Immunol.* 65:111-128.
	258.	Jhee, S. et al. (2001). "β-Amyloid Therapies in Alzheimer's Disease," *Expert Opinion on Investigational Drugs* 10(4):593-605.
	259.	Johnson, K. S. et al. (1993). "Human Antibody Engineering," *Current Opinion in Structural Biology* 3:564-571.
	260.	Jolly, D. (1994). "Viral Vector Systems for Gene Therapy," *Cancer Gene Therapy* 1(1):51-64.
	261.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," *Nature* 321:522-525.
	262.	Kabat, E. A. et al. (1991). "Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens, β_2-Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, C-Reactive Protein, Thymopoietin, Integrins, Post-gamma Globulin, α_2-Macroglobulins, and Other Related Proteins," *In* Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services NIH Publication NO. 91-3242., Fifth edition(Table of Contents only).
	263.	Kakimura, J. (2001). "BiP/GRP78-Induced Production of Cytokines and Uptake of Amyloid-β(1-42 Peptide in Microglia," *Biochemical and Biophysical Research Communications* 281(1):6-10.
	264.	Kaplitt, M. G. et al. (1994). "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," *Nature Genetics* 8:148-153.
	265.	Karlsson, R. et al. (1994). "Kinetic and Concentration Analysis Using BIA Technology," *Methods: A Companion to Methods in Enzymology* 6:99-110.
	266.	Kenney, J. S. et al. (1989). "Influence of Adjuvants on the Quantity, Affinity, Isotype and Epitope Specificity of Murine Antibodies," *J. Immunol. Methods* 121(1):157-166.
	267.	Kim, J-K. et al. (1994). "Localization of the Site of the Murine lgG1 Molecule that is Involved in Binding to the Murine Intestinal Fc Receptor," *J. Immunol.* 24:2429-2434.
	268.	Kimura, O. et al. (1994). "Retroviral Delivery of DNA Into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," *Human Gene Therapy* 5(7):845-852.
	269.	Klein, W.L. et al. (2001). "Targeting Small A Beta Oligomers: the Solution to an Alzheimers' Disease Conundrum," *Trends in Neurosciences* 24(4):219-224.
	270.	Kohler, G. et al. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," *Nature* 256:495-497.
KAB	271.	Kolls, J. et al. (1994). "Prolonged and Effective Blockade of Tumor Necrosis Factor Activity Though

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

		Adenovirus-Mediated Gene Transfer," *PNAS USA* 91:215-219.
KAB	272.	Kortt, A. A. et al. (1997). "Single-Chain Fv Fragments of Anti-Neuraminidase Antibody NC10 Containing Five- and Ten-Residue Linkers Form Dimers and With Zero-Residue Linker a Trimer," *Protein Engineering* 10(4):423-433.
	273.	Kotilinek, L.A et al. (2002). "Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease," *J. Neurosci* 22(15):6331-6335.
	274.	Kril, J. J. (2001). "Alzheimer's Disease: It's Diagnosis and Pathogenesis," *In* International Review of Neurobiology, Bradley, R. J. et al., eds., Academic Press, Inc., Volume 48 pp. 167-217.
	275.	Lee, VMY (2001). "A Beta Immunization: Moving A Beta Peptide from Brain to Blood," *PNAS* 98(16):8931-8932.
	276.	Lin, Y. M. (2001). "Amyloid Fibril Formation in Microwell Plates for Screening of Inhibitors," *Amyloid-Journal of Protein Folding Disorders* 8(3):183-193.
	277.	Lobuglio, A. F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," *PNAS USA* 86:4420-4224.
	278.	Maimone, D. et al. (2001). "Pharmacogenomics of Neurdegenerative Diseases," *European Journal of Phamacology* 413(1):11-29.
	279.	Maratea, D. et al. (1985). "Deletion and Fusion Analysis of the Phage ΦX174 Lysis Gene E," *Gene* 40:39-46.
	280.	Mark, J. D. et al. (1991). "By-Passing Immunization Human Antibodies from V-Gene Libraries Displayed on Phage," *J. Mol. Biol.* 222:581-597.
	281.	Marks, et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," *Bio/Technology* 10:779-783.
	282.	Martin, F. J. et al. (1982). "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles," *J. Biol. Chem.* 257(1):286-288.
	283.	McCafferty, J. et al. (1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," *Nature* 348:552-554.
	284.	McGowan, E. (1999). "Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes," *Neurobiology of Disease* 6:231-244.
	285.	McLaurin, J. et al. (2002). "Therapeutically Effective Antibodies Against Amyloid-β Peptide Target Amyloid-β Residues 4-10 and Inhibit Cytotoxicity and Fibrillogenesis," *Nature Medicine* 8(11):1263-1269.
	286.	Merrifield, R. B. (1963). "Solid Phase Peptide Synthesis: I. the Synthesis of a Tetrapeptide," *J. Am. Chem. Soc.* 85:2149-2146.
KAB	287.	Milstein, C. et al. (1983). "Hybrid Hybridomas and Their Use Immunohistochemistry," *Nature* 305:537-539.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	288.	Mitrasinovic, O.M. et al. (2001). "Overexpression of Macrophage Colony-Stimulating Factor Receptor on Microglial Cells Induces an Inflammatory Response," *Journal of Biological Chemistry* 276(32):30142-30149.
	289.	Mohajeri, M. H. et al. (2002). "Passive Immunization Against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer's Disease Mutation," *The Journal of Biological Chemistry* 277(36):33012-33017.
	290.	Morgan, D et al. (2000). "Aβ Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," *Nature* 408:982-985.
	291.	Morimoto, K. et al. (1992). "Single-Step Purification of $F(ab')_2$ Fragments of Mouse Monoclonal Antibodies (Immunoglobins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW," *In* Journal of Biochemical and Biophysical Methods, Chignell, C.F. et al., eds., Elsevier Science Publishers, B.V. Volume 24 pp. 107-117.
	292.	Moss, B. et al. (1989). "Vaccinia Virus Expression Vectors," *Annals of the New York Academy of Sciences: Biomedical Science and the Third World* 569:86-103.
	293.	Mullis, K.B. et al., eds. (1994). The Polymerase Chain Reaction,, Birkäuser Press, pp. xv-xvii. (Table of Contents Only)
	294.	Murphy, C.L. et al. (2001). "Chemical Typing of Amyloid Protein Contained in Formalin-Fixed Paraffin-Embedded Biopsy Specimens," *American Journal of Clinical Pathology* 116(1):135-142.
	295.	Murphy, J. R. et al (1986). "Genetic Construction, Expression, and Melanoma-Selective Cytotoxicity of a Diphtheria Toxin-Related α-Melanocyte-Stimulating Hormone Fusion Protein," *PNAS USA* 83:8258-8262.
	296.	Myers, E.W. et al. (1988). "Optimal Alignments Linear Space," *CABIOS* 4(1):11-17.
	297.	Nunan, J. et al. (2001). "The C-Terminal Fragment of the Alzheimer's Disease Amyloid Protein Precursor is Degraded by Proteasome-Dependent Mechanism Distinct from Gamma-Secretase," *European Journal of Biochemistry* 268(20):5329-5336.
	298.	Ortegà, S. et al. (1992). "Single-Step Purification on Deae-Sephacel of Recombinant Polypeptides Produced in *Escherichia Coli*,"*Biotechnology* 10:795-798.
	299.	Pfeifer, M. et al. (2002). "Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy," *Science* 298:1379.
	300.	Philip, R. et al. (1994). "Efficient and Sustained Gene Expression in Primary T. Lymphocytes and Primary and Cultured Tumor," *Mol. Cell. Biol.* 14:2411-2418.
	301.	Poljak, R. et al. (1994). "Production and Structure of Diabodies," *Structure* 2:1121-1123.
	302.	Quadt, R. et al. (1993). "Characterization of a Host Protein Associated with Brome Mosaic Virus RNA-Dependent RNA Polymerase," *PNAS USA* 90:1498-1502.
KAB	303.	Ravetch, J. V. et al. (1991). "Fc Receptors," *In* Annual Review of Immunology, Paul, W. E. et al., eds., Annual Reviews, Inc. Palo Alto, California, Volume 9 pp. 457-492. (Includes Table of Contents).

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 514712001500	Application Number 10/683,815
	Applicant Arnon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	304.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327.
	305.	Robinson, E. D. (1971). "Comparison of Labeled Trees with Valency Three," *Comb. Theor.* 11:105-119.
	306.	Rolland, A. P. (1998). "From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery," *Crit. Rev. Therap Drug Systems* 15(2):143-198.
	307.	Rosenfeld, M. A. et al. (1991). "Adenovirus-Mediated Transfer of a Recombinant αl-Antitypsin Gene to the Lung Epithelium in Vivo," *Science* 252(5004):431-434.
	308.	Saitou, N. et al. (1987). "The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Tree," *Mol. Biol. Evol.* 4:406-425.
	309.	Schier, R. et al. (1995). "Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis," *Gene* 169:147-155.
	310.	Schwartz, R. M. et al. (1978). "Matrices for Detecting Distant Relationships," Chapter 23 *In* Atlas of Protein Sequence and Structure, Library of Congress Card Catalogue Number 65-29342, ISBN 0-912466-07-03, National Biomedical Research Foundation: Maryland, Volume 5, Supplement 3 pp. 353-358.
	311.	Selkoe, D. J. (2001). "Presenilin Notch, and the Genesis and Treatment of Alzheimer's Disease," *PNAS USA* 98(20):11039-11041.
	312.	Severino, K. A. et al. (1988). "Biosynthesis of Thyrotropin releasing Hormone by a Rat Medullary Thyroid Carcinoma Cell Line," *J. Biol. Chem.* 263:620-623.
	313.	Shaw, D. R. et al. (1987). "Characterization of a Mouse/Human Chimiric Monoclonal Antibody (17-A) to a Colon Cancer Turmor-Associated Antigen," *J. Immunology* 138:4534-4538.
	314.	Sheets, M. D. et al. (1998). "Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens," *PNAS USA* 95:6157-6162.
	315.	Shenk, D. (2002). "Amyloid-β Immunotherapy for Alzheimer's Disease: the End of the Beginning," *Nature* 3:824-828.
	316.	Shenk, D. et al. (1999). "Immunization with Amyloid-β Attenuates Alzheimer Disease-Like Pathology in the PDAPP Mouse," *Nature* 400:173-177.
	317.	Shenk, D.B et al. (2000). "β-Peptide Immunization – A Possible New Treatment for Alzheimer Disease," *Archives of Neurology* 57(7):934-936.
	318.	Smith, T. W. et al. (1977). "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication," *In* Antibodies in Human Diagnosis and Therapy, Haber et al., eds, Raven Press, New York, pp. 365-389.
	319.	Sneath, P. H. A. et al., eds. (1973). Numerical Taxonomy the Principles and Practice of Numerical Classification, Freeman Press, San Francisco, pp. vi-ix,
KAB	320.	Solomon, B. et al (1996). "Monoclonal Antibodies Inhibit in vitro Fibrillar Aggregation of the

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 514712001500	Application Number 10/683,815
	Applicant Arnon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

		Alzheimer β-Amaloid Peptide," *Proc. National Acad. Sci* 93:452-455.
KAB	321.	Solomon, B. et al. (1997). "Disaggregation of Alzheimer β-amyloid by Site-Directed mAb," *PNAS* 94:4109-4112.
	322.	Stalder, M. et al. (2001). "3D-Reconstruction of Microglia and Amyloid in APP23 Transgenic Mice: No Evidence of Intracellular Amyloid," *Neurobiology of Aging* 22(3):427-434.
	323.	Steiner, H. et al. (2000). "Intramembrane Proteolysis by Presenillins," *Nature Reviews Molecular Cell Biology* 1(3):217-224.
	324.	Stoute, J. A et al. (1997). "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Faliciparum Malaria," *New Engl. J. Med.* 336(2):86-91.
	325.	Sturchler-Pierrat, C. et al. (1997). "Two Amyloid Precursor Protein Transgenic Mouse Models with Alzheimer Disease-Like Pathology," *PNAS USA* 94:13287-13292.
	326.	Suresh, M. R. et al. (1986). "Bispecific Monoclonal Antibodies from Hybrid Hybridomas," Chapter 17 *In* Methods in Enzymology Volume 121 pp. 211-229.
	327.	Tanzi, R. E. et al. (1996). "The Gene Defects Responsible for Familial Suzanne Y. Guenette, and Wilma Wasco," *Neurobiol. Dis.* 3:159-168.
	328.	Town, T. et al. (2001). "Characterization of Murine Immunoglobulin G Antibodies Against Human Amyloid-β1-42," *Neuroscience Letters* 307:101-104.
	329.	Turner, R. S. (2001). "Alzheimer's Disease in Man and Transgenic Mice – Females at Higher Risk,"Article no. 0016 *American Journal of Pathology* 158(3):797-801.
	330.	Ulmer, J. B. et al. (1993). "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," *Science* 259:1745-1749.
	331.	Umana , P. et al. (1999). "Engineered Glycoforms of an Antieuroblastorama lgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity," *Nature Biotech* 17:176-180.
	332.	Vaughan, T. J. et al. (1996). "Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-Immunized Phage Display Library," *Nature Biotechnology* 14:309-314.
	333.	Verhoeyen, M. et al. (1988). "Reshaping Human Antibodies: Grafting and Antilysozyme Activity," *Science* 239:1534-1536.
	334.	Walker, L.C et al. (2000). "The Cerebral Proteopahties – Neurodegenerative disorders of Protein Conformation and Assembly," *Molecular Neurobiology* 21(1-2):83-95.
	335.	Waterhouse, P. et al. (1993). "Combinatorial Infection and In-Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," *Nucl. Acids Res.* 21:2265-2266.
	336.	Weggen, S. et al. (2001). "A Subset of NSAIDs Lower Amyloidogenic Aβ42 Independently of Cyclooxygenase Activity," *Nature* 414:212-216.
	337.	Weninger, S.C. et al. (2001). "Inflammation and Alzheimer Disease: the Good, The Bad, and The Ugly," *Nature Medicine* 7(5):527-528.
KAB	338.	Wilbur, W. J. et al. (1983). "Rapid Similarity Searches of Nucleic Acid and Protein Data Banks," *PNAS USA* 80:726-730.

EXAMINER: Kimberly Bartlett	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Amon ROSENTHAL et al.	
(Use several sheets if necessary)	Filing Date October 9, 2003	Group Art Unit ~~1614~~ 1649
	Hand Delivered August 30, 2004	

KAB	339.	Wilcock, D. M. et al. (2001). "Number of Aβ Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels," *DNA and Cell Biology* 20(11):731-736.
	340.	Winkler, DT et al. (2001). "Sponteneous Hemorrhagic Stroke in a Mouse Model Cerebral Amyloid Angiopathy," *Journal of Neuroscience* 21(5):1619-1627.
	341.	Winter, G. et al. (1991). "Man-Made Antibodies," *Nature* 349:293-299.
	342.	Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," *Annu. Rev. Immunol.* 12:433-455.
	343.	Wittwer, A. J. et al. (1990). "Glycosylation at ASn-184 Inhibits the Conversation of Single-Chain to Two-Chain Tissue-Type Plasminogen Activator by Plasmin," *Biochem* 29:4175-4180.
	344.	Woffendin, C. et al. (1994). "NonViral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene Into Primary Human T Cells," *PNAS USA* 91:11581-11585.
	345.	Wright, A. and Morrison, S. L. (1997). "Effect of Glycosylation on Antibody Function: Implacations for Genetic Engineering," *TibTech* 15:26-32.
	346.	Wu, C. H. (1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo," *J. Biol. Chem.* 264:16985-16987.
	347.	Wu, G. Y. et al. (1991). "Receptor-Mediated Gene Delivery in Vivo," *The Journal of Biological Chemistry* 266(22):14338-14342
	348.	Wu, G. Y. et al. (1994). "Incorporation of Adenovirus Into a Ligand –Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," *J. Biol. Chem* 269:11542-11546.
	349.	Wyss, D. F. et al. (1996). "The Structural Role of Sugars in Glycoproteins," *Current Opinion Biotech.* 7:409-416.
	350.	Yelton, D. E. et al. (1995). "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis,"*J. Immunol.* 155:1994-2004.
	351.	Zenke, M. et al. (1990). "Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hemapopoietic Cells," *PNAS USA* 87:3655-3659.
KAB	352.	Zola, H. (1987). "Using Monoclonal Antibodies: Soluble Antigens," Chapter 6 *In* Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. pp. 147-158.

EXAMINER: Kimberly Ballard	DATE CONSIDERED: 1/13/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

OIPE
SEP 27 2005
PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (08-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	~~S. Turner~~ K. Ballard
Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	1.	US-2002/0028473-A1	03-07-2002	Averback	
	2.	US-2002/0136718-A1	09-26-2002	Raso	
	3.	US-2002/0197258-A1	12-26-2002	Ghanbari et al.	
	4.	US-2002/0197831-A1	12-26-2002	Todd et al.	
	5.	US-2003/0068316-A1	04-10-2003	Klein et al.	
	6.	US-2003/0073655-A1	04-17-2003	Chain	
	7.	US-2003/0108551-A1	06-12-2003	Nicolau et al.	
	8.	US-2003/0147882-A1	08-07-2003	Solomon et al.	
	9.	US-2003/0235872-A1	12-25-2003	Small et al.	
	10.	US-2003/0235897-A1	12-25-2003	Raso	
	11.	US-2004/0081657-A1	04-29-2004	Schenk	
	12.	US-2004/0197831-A1	10-07-2004	Weksler et al.	
	13.	US-2004/0219146-A1	11-04-2004	Schenk	
	14.	US-2004/0241164-A1	12-02-2004	Bales et al.	
	15.	US-2004/0265308-A1	12-30-2004	Schenk	
	16.	US-2005/0019328-A1	01-27-2005	Schenk	
	17.	US-2005/0019330-A1	01-27-2005	Schenk	
	18.	US-2005/0048049-A1	03-03-2005	Schenk	
	19.	US-2005/0129691-A1	06-16-2005	Gerlai	
	20.	US-5,231,170-A	07-27-1993	Averback	
	21.	US-5,688,651-A	11-18-1997	Solomon	
	22.	US-6,582,945-B1	06-24-2003	Raso	
	23.	US-6,743,427-B1	06-01-2004	Schenk	
	24.	US-6,750,324-B1	06-15-2004	Schenk et al.	
	25.	US-6,761,888-B1	07-13-2004	Schenk	
	26.	US-6,787,523-B1	09-07-2004	Schenk	
	27.	US-6,787,637-B1	09-07-2004	Schenk	
	28.	US-6,815,175-B2	11-09-2004	Weksler et al.	
KAB	29.	US-6,872,554-B2	03-29-2005	Raso	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KAB	30.	WO-90/09789-A2	09-07-1990	Averback		
	31.	WO-90/12870-A1	11-01-1990	Research Foundation for Mental Hygiene, Inc.		
	32.	WO-95/16917-A1	06-22-1995	Averback		
	33.	WO-96/15799-A1	05-30-1996	Rutgers, The State University of New Jersey		
	34.	WO-96/18900-A1	06-20-1996	Ramot-Univ. Authority For Applied Research and Industrial Development Ltd.		
	35.	WO-98/33815-A1	08-06-1998	Acumen Pharmaceuticals, Inc.		
KAB	36.	WO-00/72880-A2, A3	12-07-2000	Neuralab Limited		

Examiner Signature	Kimberly Ballard	Date Considered	1/12/06

pa-996225

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
(Use as many sheets as necessary)				Art Unit	1649
				Examiner Name	~~S. Turner~~ K. Ballard
Sheet	2	of	3	Attorney Docket Number	514712001500

	37.	WO-00/77178-A1	12-21-2000	Boston Biomedical Research Institute		
KAB	38.	WO-01/10900-A2, A3	02-15-2001	University of Southern California et al.		
	39.	WO-03/000714-A2, A3	01-03-2003	Panacea Pharmaceuticals, Inc.		
	40.	WO-03/015691-A2, A3	02-27-2003	Eli Lilly and Company		
	41.	WO-03/016467-A2, A3	02-27-2003	Eli Lilly and Company		
	42.	WO-03/039467-A2, A3	05-15-2003	Diagenics International Corporation		
	43.	WO-03/051374-A2, A3	06-26-2003	New York State Office of Mental Health		
	44.	WO-03/074081-A1	09-12-2003	Mindset Biopharmaceuticals USA Inc.		
	45.	WO-03/090772-A1	11-06-2003	Eli Lilly and Company		
	46.	WO-03/104437-A2, A3	12-18-2003	Northwestern University et al.		
	47.	WO-2004/001426-A2, A3	12-31-2003	Axonyx, Inc.		
	48.	WO-2004/024090-A2	03-25-2004	The Regents of the University of California		
	49.	WO-2004/024770-A1	03-25-2004	Universidad de Zaragoza		√
	50.	WO-2004/029630-A1	04-08-2004	Janssen Pharmaceutica N.V.		
	51.	WO-2004/032868-A2	04-22-2004	Rinat Neuroscience Corp.		
	52.	WO-2004/056318-A2	07-08-2004	New York University		
	53.	WO-2004/067561-A1	08-12-2004	Abbott GMBH & Co. KG	Translation of Abstract Only	
	54.	WO-2004/076677-A2, A3	09-10-2004	Institute for Research in Biomedicine		
	55.	WO-2004/098631-A1	11-18-2004	Universidad de Zaragoza		√
	56.	WO-2005/011599-A2	02-10-2005	Northwestern University		
	57.	WO-2005/018424-A2	03-03-2005	Research Foundation for Mental Hygiene, Inc.		
	58.	WO-2005/025516-A2	03-24-2005	The Regents of the University of California		
	59.	WO-2005/025616-A1	03-24-2005	Takeda Pharmaceutical Company Limited		√
KAB	60.	WO-2005/028511-A2	03-31-2005	Centocor, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KAB	61.	Akiyama, H. et al. (February 2004). "Specificity of Mechanisms for Plaque Removal after Aβ Immunotherapy for Alzheimer Disease," *Nature Medicine* 10(2):117-119.	
KAB	62.	Bard, F. et al. (February 18, 2003). "Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection Against Alzheimer's Disease-Like Neuropathology," *Proc. Natl. Acad. Sci. USA* 100(4):2023-2028.	

Examiner Signature	Kimberly Ballard	Date Considered	1/12/06

pa-996225

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	~~S. Turner~~ K. Ballard
Sheet	3	of	3	Attorney Docket Number	514712001500

KAB	63.	Bussière, T. et al. (September 2004). "Animal Model: Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance," *American Journal of Pathology* 165(3):987-995.	
	64.	Friend, P.J. et al. (December 15, 1999). "Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection," *Transplantation* 68(11):1632-1637.	
	65.	Gaskin, F. et al. (April 1993). "Human Antibodies Reactive with β-Amyloid Protein in Alzheimer's Disease," *J. Exp. Med.* 177:1181-1186.	
	66.	Goding, J.W. (1983). "Production of Monoclonal Antibodies" Chapter 3 In Monoclonal Antibodies: Priniciples and Practice Academic Press, Inc.:New York, NY, pgs. 56-97.	
	67.	Gregory, G.C. et al. (2005). "What is the Dominant Aβ Species in Human Brain Tissue?" *Neurotoxicity Research* 7(1,2):29-41.	
	68.	Klyubin, I. et al. (May 2005). "Amyloid β Protein Immunotherapy Neutralizes Aβ Oligomers That Disrupt Synaptic Plasticity *in vivo*," *Nature Medicine* 11(5):556-561.	
	69.	Price, D.L. et al. (July 1993). "Alzheimer Disease and the Prion Disorders Amyloid β-Protein and Prion Protein Amyloidoses," *Proc. Natl. Acad. Sci. USA* 90:6381-6384.	
	70.	Saido, T.C. et al. (May 27, 1994). "Spatial Resolution on the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," *J. Bio. Chem.* 269(21):15253-15257.	
	71.	Spillantini, M.G. et al. (May 1990). "Different Configurational States of β-Amyloid and Their Distributions Relative to Plaques and Tangles in Alzheimer Disease," *Proc. Natl. Acad. Sci. USA* 87:3947-3951.	
	72.	Sugarman, M.C. et al. (April 30, 2002). "Inclusion Body Myositis-Like Phenotype Induced by Transgenic Overexpression of βAPP in Skeletal Muscle," *Proc. Natl. Acad. Sci. USA* 99(9):6334-6339.	
	73.	Vehmas, A.K. et al. (2001). "β-Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain Aβ Levels in APPswe/PS1ΔE9 Mice, as Detected by SELDI-TOF-Based ProteinChip® Technology," *DNA and Cell Biology* 20(11):713-721.	
	74.	Walker, L.C. et al. (July 1994). "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," *Journal of Neuropathology and Experimental Neurology* 53(4):377-383.	
	75.	Wilcock, D.M. et al. (2004). "Passive Immunotherapy Against Aβ in Aged APP-Transgenic Mice Reverses Cognitive Deficits and Depletes Parenchymal Amyloid Deposits in Spite of Increased Vascular Amyloid and Microhemorrhage," *Journal of Neuroinflammation* 1:1-11.	
KAB	76.	Wilcock, D.M. et al. (July 7, 2004). "Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition," *The Journal of Neuroscience* 24(27):6144-6151.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Kimberly Ballard	Date Considered	1/12/06

pa-996225